

Table S1 Dosage and schedule of the treatment regimen

Regimen	Drug dosage	Schedule	Duration
SOX	Oxaliplatin: 130mg/m ² IV	Days 1	Q3wk, up to 8
	S-1: 80mg (<1.25m ²); 100mg (1.25-1.5m ²); 120mg (>1.5m ²) PO	Days 1-14	cycles
CapeOX	Oxaliplatin: 130mg/m ² IV	Days 1	Q3wk, up to 8
	Capecitabine: 1000 mg/m ² PO	Days 1-14	cycles
FOLFOX	Oxaliplatin: 85 mg/m ² IV	Days 1	Q2wk, up to 12
	Leucovorin: 400 mg/m ² IV	Days 1	cycles
	5-Fu: 400 mg/m ² IVP	Days 1	
	5-Fu (continuous): 2400-3000 mg/m ² IV	Days 1-2	
CS	Cisplatin: 60 mg/m ² IV	Days 1	Q3wk, up to 8
	S-1: 80mg (<1.25m ²); 100mg (1.25-1.5m ²); 120mg (>1.5m ²) PO	Days 1-14	cycles
PS	Paclitaxel: 80 mg/m ² IV	Days 1, 8	Q3wk, up to 8
	S-1: 80mg (<1.25m ²); 100mg (1.25-1.5m ²); 120mg (>1.5m ²) PO	Days 1-14	cycles
PX	Paclitaxel: 80 mg/m ² IV	Days 1, 8	Q3wk, up to 8
	Capecitabine: 1000 mg/m ² PO	Days 1-14	cycles
POS	Paclitaxel: 120 mg/m ² IV	Days 1	Q2wk, up to 6
	Oxaliplatin: 185mg/m ² IV	Days 1	cycles
	S-1: 40mg (<1.25m ²); 50mg (1.25-1.5m ²); 60mg (>1.5m ²) PO	Days 1-7	

Abbreviations: PO, by oral; IV, intra venous

Table S2 Patient characteristics categorized by JGCA2017-TRG system

Characteristics	JGCA2017-TRG						P value
	3	2b	2a	1b	1a	0	
No. of patients	36	39	29	78	205	26	
(%)	(8.72)	(9.44)	(7.02)	(18.89)	(49.64)	(6.30)	
Age, median (IQR), y	60.5 (57.5-69)	62 (51-67)	64 (58-70)	60.5 (52-68)	60 (53-66)	61 (55-65)	0.340
BMI, median (IQR), (kg/m ²)	22.65 (21.28-25.17)	21.36 (20.03-23.78)	23.51 (21.71-25.81)	23.56 (20.70-25.50)	23.05 (20.94-25.15)	23.83 (21.55-24.74)	0.285
Male	24 (66.67)	22 (56.41)	25 (86.21)	52 (66.67)	161 (78.54)	20 (76.92)	0.017
ASA score							0.884
1	6 (16.67)	9 (23.08)	7 (24.14)	21 (26.92)	50 (24.39)	9 (34.62)	
2	24 (66.67)	27 (69.23)	18 (62.07)	45 (57.69)	126 (61.46)	15 (67.69)	
3	6 (16.67)	3 (7.69)	4 (13.79)	12 (15.38)	29 (14.15)	2 (7.69)	
ECOG							0.128
0	24 (66.67)	19 (48.72)	11 (37.93)	42 (53.85)	122 (59.51)	11 (42.31)	
1	9 (25.00)	18 (46.15)	17 (58.62)	32 (41.03)	77 (37.56)	15 (57.69)	
2	3 (8.33)	2 (5.13)	1 (3.45)	4 (5.13)	6 (2.93)	0 (0.00)	
Location							0.199
Upper	17 (47.22)	13 (33.33)	12 (41.38)	30 (38.46)	81 (39.51)	13 (50.00)	
Middle	2	6	3	10	27	3	

		(5.56)	(15.38)	(10.34)	(12.82)	(13.17)	(11.54)	
Lower		17	17	9	33	88	6	
		(47.22)	(43.59)	(31.03)	(42.31)	(42.93)	(23.08)	
Diffuse		0	3	5	5	9	4	
		(0.00)	(7.69)	(17.24)	(6.41)	(4.39)	(15.38)	
Diameter (cm)		0 (0-0)	2	2	2.5	3	3.25	<0.001
			(1.00-3.00)	(1.00-4.00)	(2.00-3.50)	(2.00-5.00)	(2.00-4.00)	
Differentiation								0.261
Well		1	3	0	2	18	3	
		(2.78)	(7.69)	(0.00)	(2.56)	(8.78)	(11.54)	
Moderate		17	15	12	28	93	12	
		(47.22)	(38.46)	(41.38)	(35.90)	(45.37)	(46.15)	
Poor		18	21	17	48	94	11	
		(50.00)	(53.85)	(58.62)	(61.54)	(45.85)	(42.31)	
Mucinous or signet cell		7	10	6	20	39	3	0.629
		(19.44)	(25.64)	(20.69)	(25.64)	(19.02)	(11.54)	
LVI		0	4	6	25	86	11	<0.001
		(0.00)	(10.26)	(20.69)	(32.05)	(41.95)	(42.31)	
Cycles of treatment		3 (2-3)	2 (2-3)	2 (2-3)	2 (2-3)	2 (2-3)	3 (2-3)	0.351
ypT								<0.001
ypT0		36	1	0	0	0	0	
		(100.0)	(2.56)	(0.00)	(0.00)	(0.00)	(0.00)	
ypT1		0	9	2	2	9	3	
		(0.00)	(23.08)	(6.90)	(2.56)	(4.39)	(11.54)	
ypT2		0	8	7	14	24	2	
		(0.00)	(20.51)	(24.14)	(17.95)	(11.71)	(7.69)	
ypT3		0	7	7	18	34	0	
		(0.00)	(17.95)	(24.14)	(23.08)	(16.59)	(0.00)	
ypT4		0	14	13	44	138	21	

	(0.00)	(35.90)	(44.83)	(56.41)	(67.32)	(80.77)	
ypN							<0.001
N0	31	25	13	28	64	8	
	(86.11)	(64.10)	(44.83)	(35.90)	(31.22)	(30.77)	
N1	5	4	4	14	36	1	
	(13.89)	(10.26)	(13.79)	(17.95)	(17.56)	(3.85)	
N2	0	6	4	13	40	7	
	(0.00)	(15.38)	(13.79)	(16.67)	(19.51)	(26.92)	
N3	0	4	8	23	65	10	
	(0.00)	(10.26)	(27.59)	(29.49)	(31.71)	(38.46)	
ypStage							<0.001
pCR	31	1	0	0	0	0	
	(86.11)	(2.56)	(0.00)	(0.00)	(0.00)	(0.00)	
I	5	13	5	9	21	4	
	(13.89)	(33.33)	(17.24)	(11.54)	(10.24)	(15.38)	
II	0	16	11	26	58	5	
	(0.00)	(41.03)	(37.93)	(33.33)	(28.29)	(19.23)	
III	0	9	13	43	126	17	
	(0.00)	(23.08)	(44.83)	(55.13)	(61.46)	(65.38)	
Total	10	15	16	33	92	14	0.223
gastrectomy	(27.78)	(38.46)	(55.17)	(42.31)	(44.88)	(53.85)	
Regimen							0.035
Platin-based	34	38	26	72	173	21	
	(94.44)	(97.44)	(89.66)	(92.31)	(84.39)	(80.77)	
Taxol-based	1	1	2	3	18	0	
	(2.78)	(2.56)	(6.90)	(3.85)	(8.78)	(0.00)	
Triplet	1	0	1	3	14	5	
	(2.78)	(0.00)	(3.45)	(3.85)	(6.83)	(19.23)	
Adjuvant	28	29	22	62	149	18	0.850
chemotherapy	(77.78)	(74.36)	(75.86)	(79.49)	(72.68)	(69.23)	
Postoperative							0.461

complications

Grade 0-1	27	27	18	49	135	21	0.461
	(75.00)	(69.23)	(62.07)	(62.82)	(65.85)	(80.77)	
Grade 2	7	4	7	19	39	2	
	(19.44)	(10.26)	(24.14)	(24.36)	(19.02)	(7.69)	
Grade 3-4	2	8	4	10	31	3	
	(5.56)	(20.51)	(13.79)	(12.82)	(15.12)	(11.54)	

Values in parentheses are percentages unless indicated otherwise; BMI, Body Mass Index; ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; NACT, neoadjuvant chemotherapy.

Table S3 Patient characteristics categorized by JGCA-TRG (2011) system

Characteristics	AJCC-TRG					P value
	3	2	1b	1a	0	
No. of patients	36 (8.72)	68	78	205	26 (6.30)	
(%)		(16.46)	(18.89)	(49.64)		
Age, median (IQR), y	60.5 (57.5-69)	63.5 (54.5-68.5)	60.5 (52-68)	60 (53-66)	61 (55-65)	0.528
BMI, median (IQR), (kg/m ²)	22.65 (21.28-25.17)	22.29 (20.69-24.74)	23.56 (20.70-25.50)	23.05 (20.94-25.15)	23.83 (21.55-24.74)	0.855
Male	24 (66.67)	47 (69.12)	52 (66.67)	161 (78.54)	20 (76.92)	0.182
ASA score						0.809
1	6 (16.67)	16 (23.53)	21 (26.92)	50 (24.39)	9 (34.62)	
2	24 (66.67)	45 (66.18)	45 (57.69)	126 (61.46)	15 (67.69)	
3	6 (16.67)	7 (10.29)	12 (15.38)	29 (14.15)	2 (7.69)	
ECOG						0.082
0	24 (66.67)	30 (44.12)	42 (53.85)	122 (59.51)	11 (42.31)	
1	9 (25.00)	35 (51.47)	32 (41.03)	77 (37.56)	15 (57.69)	
2	3 (8.33)	3 (4.41)	4 (5.13)	6 (2.93)	0 (0.00)	
Location						0.207
Upper	17 (47.22)	25 (36.76)	30 (38.46)	81 (39.51)	13 (50.00)	
Middle	2 (5.56)	9 (13.24)	10	27	3 (11.54)	

			(12.82)	(13.17)		
Lower	17	26	33	88	6 (23.08)	
	(47.22)	(38.24)	(42.31)	(42.93)		
Diffuse	0 (0.00)	8 (11.76)	5 (6.41)	9 (4.39)	4 (15.38)	
Diameter (cm)	0 (0-0)	2 (1-4)	2.5	3 (2.00-3.25)	3.25	<0.001
			(2.00-3.50)	(2.00-5.00)	(2.00-4.00)	
Differentiation						0.216
Well	1 (2.78)	3 (4.41)	2 (2.56)	18 (8.78)	3 (11.54)	
Moderate	17	27	28	93	12	
	(47.22)	(39.71)	(35.90)	(45.37)	(46.15)	
Poor	18	38	48	94	11	
	(50.00)	(55.88)	(61.54)	(45.85)	(42.31)	
Mucinous or signet cell	7 (19.44)	16	20	39	3 (11.54)	0.522
		(23.53)	(25.64)	(19.02)		
LVI	0 (0.00)	10	25	86	11	<0.001
		(14.71)	(32.05)	(41.95)	(42.31)	
Cycles of treatment	3 (2-3)	2 (2-3)	2 (2-3)	2 (2-3)	3 (2-3)	0.241
ypT						<0.001
ypT0	36	1 (1.47)	0 (0.00)	0 (0.00)	0 (0.00)	
	(100.0)					
ypT1	0 (0.00)	11	2 (2.56)	9 (4.39)	3 (11.54)	
		(16.18)				
ypT2	0 (0.00)	15	14	24	2 (7.69)	
		(22.06)	(17.95)	(11.71)		
ypT3	0 (0.00)	24	18	34	0 (0.00)	
		(20.59)	(23.08)	(16.59)		
ypT4	0 (0.00)	27	44	138	21	
		(39.71)	(56.41)	(67.32)	(80.77)	
ypN						<0.001

N0	31 (86.11)	38 (55.88)	28 (35.90)	64 (31.22)	8 (30.77)	
N1	5 (13.89)	8 (11.76)	14 (17.95)	36 (17.56)	1 (3.85)	
N2	0 (0.00)	10 (14.71)	13 (16.67)	40 (19.51)	7 (26.92)	
N3	0 (0.00)	12 (17.65)	23 (29.49)	65 (31.71)	10 (38.46)	
ypStage						<0.001
pCR	31 (86.11)	1 (1.47)	0 (0.00)	0 (0.00)	0 (0.00)	
I	5 (13.89)	18 (26.47)	9 (11.54)	21 (10.24)	4 (15.38)	
II	0 (0.00)	27 (39.71)	26 (33.33)	58 (28.29)	5 (19.23)	
III	0 (0.00)	22 (32.35)	43 (55.13)	126 (61.46)	17 (65.38)	
Total	10 (27.78)	31 (45.59)	33 (42.31)	92 (44.88)	14 (53.85)	0.280
gastrectomy						
Regimen						0.018
Platin-based	34 (94.44)	64 (94.12)	72 (92.31)	173 (84.39)	21 (80.77)	
Taxol-based	1 (2.78)	3 (4.41)	3 (3.85)	18 (8.78)	0 (0.00)	
Triplet	1 (2.78)	1 (1.47)	3 (3.85)	14 (6.83)	5 (19.23)	
Adjuvant	28 (77.78)	51 (75.00)	62 (79.49)	149 (72.68)	18 (69.23)	0.741
chemotherapy						
Postoperative						0.493
complications						
Grade 0-1	27 (75.00)	45 (66.18)	49 (62.82)	135 (65.85)	21 (80.77)	
Grade 2	7 (19.44)	11	19	39	2 (7.69)	

		(16.18)	(24.36)	(19.02)	
Grade 3-4	2 (5.56)	12	10	31	3 (11.54)
		(17.65)	(12.82)	(15.12)	

Values in parentheses are percentages unless indicated otherwise; BMI, Body Mass Index; ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; NACT, neoadjuvant chemotherapy.

Table S4 Patient characteristics categorized by Becker-TRG system

Characteristics	Becker-TRG				P value
	0	1	2	3	
No. of patients (%)	36 (8.72)	39 (9.44)	65 (15.74)	273 (66.10)	
Age, median (IQR), y	60.5 (57.5-69)	62 (51-67)	63 (55-70)	60 (53-66)	0.155
BMI, median (IQR), (kg/m ²)	22.65 (21.28-25.17)	21.36 (20.03-23.78)	21.36 (21.55-25.95)	22.65 (21.28-25.17)	0.103
Male	24 (66.67)	22 (56.41)	48 (73.85)	210 (76.92)	0.039
ASA score					0.339
1	6 (16.67)	9 (23.08)	19 (29.23)	68 (24.91)	
2	24 (66.67)	27 (69.23)	33 (50.77)	171 (62.64)	
3	6 (16.67)	3 (7.69)	13 (20.00)	34 (12.45)	
ECOG					0.086
0	24 (66.67)	19 (48.72)	31 (47.69)	155 (56.78)	
1	9 (25.00)	18 (46.15)	29 (44.62)	112 (41.03)	
2	3 (8.33)	2 (5.13)	5 (7.69)	6 (2.20)	
Location					0.524
Upper	17 (47.22)	13 (33.33)	26 (40.00)	110 (40.29)	
Middle	2 (5.56)	6 (15.38)	9 (13.85)	34 (12.45)	
Lower	17 (47.22)	17 (43.59)	23 (35.38)	113 (41.39)	
Diffuse	0 (0.00)	3 (7.69)	7 (10.77)	16 (5.86)	
Diameter (cm)	2.00 (1.00-	2.00 (1.00-	2.00 (1.00-	3.00 (2.00-	0.001

		3.00)	3.00)	3.00)	5.00)	
Differentiation						0.051
Well		1 (2.78)	3 (7.69)	0 (0.00)	23 (8.42)	
Moderate		17 (47.22)	15 (38.46)	22 (33.85)	123 (45.05)	
Poor		18 (50.00)	21 (53.85)	43 (66.15)	127 (46.52)	
Mucinous signet cell	or	7 (19.44)	10 (25.64)	16 (24.62)	52 (19.05)	0.642
LVI		0 (0.00)	4 (10.26)	15 (23.08)	113 (41.39)	<0.001
Cycles treatment	of	3 (2-3)	2 (2-3)	2 (2-3)	2 (2-3)	0.227
ypT						<0.001
ypT0		36 (100.00)	1 (2.56)	0 (0.00)	0 (0.00)	
ypT1		10 (20.83)	9 (23.08)	3 (4.62)	13 (4.76)	
ypT2		0 (0.00)	8 (20.51)	16 (24.62)	31 (11.36)	
ypT3		0 (0.00)	7 (17.95)	13 (20.00)	46 (16.85)	
ypT4		0 (0.00)	14 (35.90)	33 (50.77)	183 (67.03)	
ypN						<0.001
N0		31 (86.11)	25 (64.10)	29 (44.62)	84 (30.77)	
N1		5 (13.89)	4 (10.26)	10 (15.38)	45 (16.48)	
N2		0 (0.00)	6 (15.38)	9 (13.85)	55 (20.15)	
N3		0 (0.00)	4 (10.26)	17 (26.15)	89 (32.60)	
ypStage						<0.001
pCR		31 (86.11)	1 (2.56)	0 (0.00)	0 (0.00)	
I		5 (13.89)	13 (33.33)	12 (18.46)	27 (9.89)	
II		0 (0.00)	16 (41.03)	22 (33.85)	78 (28.57)	
III		0 (0.00)	9 (23.08)	31 (47.69)	168 (61.54)	

Total gastrectomy	10 (27.78)	15 (38.46)	32 (49.23)	151 (55.31)	0.134
Regimen					0.124
Platin-based	34 (94.44)	38 (97.44)	60 (92.31)	232 (84.98)	
Taxol-based	1 (2.78)	1 (2.56)	4 (6.15)	19 (6.96)	
Triplet	1 (2.78)	0 (0.00)	1 (1.54)	22 (8.06)	
Adjuvant chemotherapy	28 (77.78)	29 (74.36)	51 (78.46)	200 (73.26)	0.810
Postoperative complications					0.384
Grade 0-1	27 (75.00)	27 (69.23)	40 (61.54)	183 (67.03)	
Grade 2	7 (19.44)	4 (10.26)	16 (24.62)	51 (18.68)	
Grade 3-4	2 (5.56)	8 (20.51)	9 (13.85)	39 (14.29)	

Table S5 Patient characteristics categorized by AJCC/CAP-TRG system

Characteristics	Total	AJCC-TRG				P value
		0	1	2	3	
No. of patients	413	36 (8.72)	48	89	240	
(%)			(11.62)	(21.55)	(58.11)	
Age, median (IQR), y	61 (54-67)	60.5 (57.5-69)	63.5 (54-68.5)	61 (52-67)	60 (54-67)	0.548
BMI, median (IQR), (kg/m ²)	23.04 (20.83-25.10)	22.65 (21.28-25.17)	21.41 (19.98-24.05)	23.66 (21.08-25.50)	23.24 (20.96-25.03)	0.210
Male	304 (73.61)	24 (66.67)	30 (62.50)	67 (75.28)	183 (76.25)	0.177
ASA score						0.844
1	102 (24.70)	6 (16.67)	15 (31.25)	22 (24.72)	59 (24.58)	
2	255 (61.74)	24 (66.67)	28 (58.33)	54 (60.67)	149 (62.08)	
3	56 (13.56)	6 (16.67)	5 (10.42)	13 (14.61)	32 (13.33)	
ECOG						0.144
0	229 (55.45)	24 (66.67)	21 (43.75)	51 (57.30)	133 (55.42)	
1	168 (40.68)	9 (25.00)	24 (50.00)	35 (39.33)	100 (41.67)	
2	16 (3.87)	3 (8.33)	3 (6.25)	3 (3.37)	7 (2.92)	
Location						0.429
Upper	166 (40.19)	17 (47.22)	15 (31.25)	34 (38.20)	100 (41.67)	
Middle	51 (12.35)	2 (5.56)	8 (16.67)	15 (16.85)	26 (10.83)	
Lower	170	17	21	34	98	

		(41.16)	(47.22)	(43.75)	(38.20)	(40.83)	
Diffuse		26 (6.30)	0 (0.00)	4 (8.33)	6 (6.74)	16 (6.67)	
Diameter (cm)		0 (0,0)	2.00 (1.00- 3.00)	2 (2.00- 3.00)	2 (2.00- 3.00)	3 (2.00- 5.00)	
Differentiation							0.342
Well		27 (6.54)	1 (2.78)	3 (6.25)	2 (2.25)	21 (8.75)	
Moderate		177 (42.86)	17 (47.22)	17 (35.42)	39 (43.82)	104 (43.33)	
Poor		209 (50.61)	18 (50.00)	28 (58.33)	48 (53.93)	115 (47.92)	
Mucinous or signet cell		85 (20.58)	7 (19.44)	11 (22.92)	21 (23.60)	46 (19.17)	0.807
LVI		132 (31.96)	0 (0.00)	6 (12.50)	23 (25.84)	103 (42.92)	<0.001
Cycles of treatment		2 (2-3)	3 (2-3)	2.5 (2-3)	2 (2-3)	2 (2-3)	0.295
ypT							
ypT0		37 (8.96)	36 (100.00)	1 (2.08)	0 (0.00)	0 (0.00)	<0.001
ypT1		25 (6.05)	10 (20.83)	10 (20.83)	2 (2.25)	13 (5.42)	
ypT2		55 (13.32)	0 (0.00)	10 (20.83)	20 (22.47)	25 (10.42)	
ypT3		66 (15.98)	0 (0.00)	10 (20.83)	18 (20.22)	38 (15.83)	
ypT4		230	0 (0.00)	17 (35.42)	49 (55.06)	164 (68.33)	
ypN							<0.001
N0		169 (40.92)	31 (86.11)	26 (54.17)	38 (42.70)	74 (30.83)	

N1	64 (15.50)	5 (13.89)	7 (14.58)	18 (20.22)	34 (14.17)	
N2	70 (16.95)	0 (0.00)	9 (18.75)	12 (13.48)	49 (20.42)	
N3	110 (26.63)	0 (0.00)	6 (12.50)	21 (23.60)	83 (34.58)	
ypStage						<0.001
pCR	32 (7.75)	31 (86.11)	1 (2.08)	0 (0.00)	0 (0.00)	
I	57 (13.80)	5 (13.89)	14 (29.17)	13 (14.61)	25 (10.42)	
II	116 (28.09)	0 (0.00)	18 (37.50)	36 (40.45)	62 (25.83)	
III	208 (50.36)	0 (0.00)	15 (31.25)	40 (44.94)	153 (63.75)	
Total	180 (43.58)	10 (27.78)	18 (37.50)	42 (47.19)	110 (45.83)	0.148
gastrectomy						
Regimen						0.211
Platin-based	364 (88.14)	34 (94.44)	46 (95.83)	81 (91.01)	203 (84.58)	
Taxol-based	25 (6.05)	1 (2.78)	1 (2.08)	6 (6.74)	17 (7.08)	
Triplet	24 (5.81)	1 (2.78)	1 (2.08)	2 (2.25)	20 (8.33)	
Adjuvant	308 (74.58)	28 (77.78)	36 (75.00)	71 (79.78)	173 (72.08)	0.521
chemotherapy						
Postoperative						0.831
complications						
Grade 0-1	277 (67.07)	27 (75.00)	32 (66.67)	58 (65.17)	160 (66.67)	
Grade 2	78 (18.89)	7 (19.44)	9 (18.75)	16 (17.89)	46 (19.17)	
Grade 3-4	58	2 (5.56)	7 (14.58)	15	34	

(14.04)

(16.85) (14.17)

Values in parentheses are percentages unless indicated otherwise; BMI, Body Mass Index; ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; NACT, neoadjuvant chemotherapy.

Table S6 Patient characteristics categorized by Mandard-TRG system

Characteristics	Mandard-TRG					P value
	1	2	3	4	5	
No. of patients	36 (8.72)	48	89	214	26 (6.30)	
(%)		(11.62)	(21.55)	(51.82)		
Age, median (IQR), y	60.5 (57.5-69)	63.5 (54-68.5)	61 (52-67)	60 (54-67)	61 (55-65)	
BMI, median (IQR), (kg/m ²)	22.65 (21.28-25.17)	21.41 (19.98-24.05)	23.66 (21.08-25.50)	23.04 (20.83-25.26)	23.83 (21.55-24.74)	
Male	24 (66.67)	30 (62.50)	67 (75.28)	163 (76.17)	20 (76.92)	0.294
ASA score						0.791
1	6 (16.67)	15 (31.25)	22 (24.72)	50 (23.36)	9 (34.62)	
2	24 (66.67)	28 (58.33)	54 (60.67)	134 (62.62)	15 (57.69)	
3	6 (16.67)	5 (10.42)	13 (14.61)	30 (14.02)	2 (7.69)	
ECOG						0.155
0	24 (66.67)	21 (43.75)	51 (57.30)	122 (57.01)	11 (42.31)	
1	9 (25.00)	24 (50.00)	35 (39.33)	85 (39.72)	15 (67.69)	
2	3 (8.33)	3 (6.25)	3 (3.37)	7 (3.27)	0 (0.00)	
Location						0.235
Upper	17 (47.22)	15 (31.25)	34 (38.20)	87 (40.65)	13 (50.00)	
Middle	2 (5.56)	8 (16.67)	15 (16.85)	23 (10.75)	3 (11.54)	
Lower	17	21	34	92	6 (23.08)	

		(47.22)	(43.75)	(38.20)	(42.99)	
Diffuse		0 (0.00)	4 (8.33)	6 (6.74)	12 (5.61)	4 (15.38)
Diameter (cm)		2.00	2.00	2.00	3.00	3.25
		(1.00-3.00)	(2.00-3.00)	(2.00-3.00)	(2.00-5.00)	(2.00-4.00)
Differentiation						0.475
Well		1 (2.78)	3 (6.25)	2 (2.25)	18 (8.41)	3 (11.54)
Moderate		17	17	39	92	12
		(47.22)	(35.42)	(43.82)	(42.99)	(46.15)
Poor		18	28	48	104	11
		(50.00)	(58.33)	(53.93)	(48.60)	(42.31)
Mucinous	or	7 (19.44)	11	21	43	3 (11.54)
signet cell			(22.92)	(23.60)	(20.09)	
LVI		0 (0.00)	6 (12.50)	23	92	11
				(25.84)	(42.99)	(42.31)
Cycles	of	3 (2-3)	2.5 (2-3)	2 (2-3)	2 (2-3)	3 (2-3)
treatment						
ypT						<0.001
ypT0		36	1 (2.08)	0 (0.00)	0 (0.00)	0 (0.00)
		(100.00)				
ypT1		10	10	2 (2.25)	10 (4.67)	3 (11.54)
		(20.83)	(20.83)			
ypT2		0 (0.00)	10	20	23	2 (7.69)
			(20.83)	(22.47)	(10.75)	
ypT3		0 (0.00)	10	18	38	0 (0.00)
			(20.83)	(20.22)	(17.76)	
ypT4		0 (0.00)	17	49	143	21
			(35.42)	(55.06)	(66.82)	(80.77)
ypN						<0.001
N0		31	26	38	66	8 (30.77)
		(86.11)	(54.17)	(42.70)	(30.84)	

N1	5 (13.89)	7 (14.58)	18 (20.22)	33 (15.42)	1 (3.85)	
N2	0 (0.00)	9 (18.75)	12 (13.48)	42 (19.63)	7 (26.92)	
N3	0 (0.00)	6 (12.50)	21 (23.60)	73 (34.11)	10 (38.46)	
ypStage						<0.001
pCR	31 (86.11)	1 (2.08)	0 (0.00)	0 (0.00)	0 (0.00)	
I	5 (13.89)	14 (29.17)	13 (14.61)	21 (9.81)	4 (15.38)	
II	0 (0.00)	18 (37.50)	36 (40.45)	57 (26.64)	5 (19.23)	
III	0 (0.00)	15 (31.25)	40 (44.94)	136 (63.55)	17 (65.38)	
Total	10 (27.78)	18 (37.50)	42 (47.19)	96 (44.86)	14 (53.85)	0.191
gastrectomy						
Regimen						0.021
Platin-based	34 (94.44)	46 (95.83)	81 (91.01)	182 (85.05)	21 (80.77)	
Taxol-based	1 (2.78)	1 (2.08)	6 (6.74)	17 (7.94)	0 (0.00)	
Triplet	1 (2.78)	1 (2.08)	2 (2.25)	15 (7.01)	5 (19.23)	
Adjuvant	28 (77.78)	36 (75.00)	71 (79.78)	155 (72.43)	18 (69.23)	0.666
chemotherapy						
Postoperative						0.664
complications						
Grade 0-1	27 (75.00)	32 (66.67)	58 (65.17)	139 (64.95)	21 (80.77)	
Grade 2	7 (19.44)	9 (18.75)	16 (17.89)	44 (20.56)	2 (7.69)	
Grade 3-4	2 (5.56)	7 (14.58)	15	31	3 (11.54)	

(16.85) (14.49)

Values in parentheses are percentages unless indicated otherwise; BMI, Body Mass Index; ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; NACT, neoadjuvant chemotherapy.